| Trough infliximab concentrations predict efficacy and sustained control of disease activity in rheumatoid arthritis. | |
| | |
MedLine Citation:
|
PMID: 20216124 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Infliximab is a chimeric monoclonal antibody that binds to human tumor necrosis factor alpha and is approved for refractory rheumatoid arthritis. We studied the association between infliximab concentration and long-term control of disease activity in patients with rheumatoid arthritis treated on a routine basis both in cross-sectional analysis and over the long term. Trough serum infliximab concentrations were measured in patients with rheumatoid arthritis receiving infliximab infusions during the period August to October 2006. Disease activity was assessed by the Disease Activity Score for 28 Joints (DAS28) and usual biologic markers. During a 42-week follow-up period, patients were classified into two groups: those continuing with the same or lower doses of infliximab (Group A = treatment success) and those who switched to another biopharmaceutical or required an increase in infliximab dose (Group B = treatment failure). Treatment maintenance for Group A was analyzed by categories of infliximab concentration at baseline and compared by the log rank test. In 28 patients, C-reactive protein and infliximab concentrations were inversely related. Infliximab concentration in patients with low disease activity (DAS28 3.2 or less) was higher than in those with persistent active disease (DAS28 greater than 3.2); median values were 3.26 and 0.16 mg/L, respectively (P < 0.01). Analysis after 42 weeks showed that patients in Group A had higher infliximab concentrations at baseline than those with treatment failure (P < 0.01). In rheumatoid arthritis, infliximab concentration is predictive of sustained efficacy with the same infliximab regimen and should be considered on a routine basis. |
| | |
Authors:
|
Denis Mulleman; Delphine Chu Miow Lin; Emilie Ducourau; Patrick Emond; David Ternant; Charlotte Magdelaine-Beuzelin; Jean-Pierre Valat; Gilles Paintaud; Philippe Goupille |
Related Documents
:
|
433944 - Pericardial disease in rheumatoid arthritis. 795004 - Hla-antigen b27 in cases with joint affections in an outbreak of salmonellosis. 9456634 - In vitro synthesis of prostaglandin e2 by synovial tissue after helium-neon laser radia... 11196524 - The arthritis of inflammatory childhood myositis syndromes. 16115484 - Interleukin-18: interleukin-10 ratio and in-hospital adverse events in patients with ac... 10483324 - Vascular 131i-low-density lipoprotein imaging in patients with hypertension and early a... |
Publication Detail:
|
Type: Comparative Study; Journal Article |
Journal Detail:
|
Title: Therapeutic drug monitoring Volume: 32 ISSN: 1536-3694 ISO Abbreviation: Ther Drug Monit Publication Date: 2010 Apr |
Date Detail:
|
Created Date: 2010-03-30 Completed Date: 2010-11-05 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 7909660 Medline TA: Ther Drug Monit Country: United States |
Other Details:
|
Languages: eng Pagination: 232-6 Citation Subset: IM |
Affiliation:
|
Université François Rabelais de Tours, CNRS, UMR 6239, Tours, France. mulleman@univ-tours.fr |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Aged Aged, 80 and over Antibodies, Monoclonal / administration & dosage*, blood* Arthritis, Rheumatoid / blood*, drug therapy* Cross-Sectional Studies Delayed-Action Preparations / administration & dosage, pharmacokinetics Female Follow-Up Studies Humans Male Middle Aged Predictive Value of Tests Treatment Outcome |
| Chemical | |
Reg. No./Substance:
|
0/Antibodies, Monoclonal; 0/Delayed-Action Preparations; 0/infliximab |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Clinical Repercussions of Analytical Interferences Due to Aldosterone Antagonists in Digoxin Immunoa...
Next Document: Osteonecrosis in Patients After Severe Acute Respiratory Syndrome (SARS): Possible Role of Anticardi...